威尔药业(603351) - 2019 Q3 - 季度财报

Financial Performance - Revenue for the period from January to September reached CNY 660,725,633.35, a 10.14% increase year-on-year[7] - Net profit attributable to shareholders increased by 31.24% to CNY 110,375,884.96 for the period from January to September[7] - Net profit attributable to shareholders after deducting non-recurring gains and losses increased by 32.99% to CNY 105,779,911.41[7] - Basic and diluted earnings per share were both CNY 1.21, a slight increase of 0.83% compared to the previous year[7] - The company reported a total profit of ¥39,725,734.77 for Q3 2019, which is a 47.0% increase from ¥26,994,605.96 in Q3 2018[28] - The net profit for Q3 2019 reached ¥34,547,080.84, up 47.3% from ¥23,468,920.53 in Q3 2018[31] - The total comprehensive income for Q3 2019 was ¥34,547,080.84, compared to ¥23,468,920.53 in Q3 2018, indicating a growth of 47.3%[32] Assets and Liabilities - Total assets increased by 80.03% to CNY 1,455,038,160.29 compared to the end of the previous year[7] - Total liabilities reached CNY 231,554,920.11, compared to CNY 193,588,491.37, marking an increase of around 20%[20] - Current assets totaled CNY 1,082,505,778.67, compared to CNY 479,280,046.05 in the previous year, reflecting a growth of about 126%[23] - Non-current assets amounted to CNY 351,087,939.70, an increase from CNY 310,787,581.81, indicating a growth of approximately 13%[23] - Total liabilities increased to ¥202,263,140.90 in Q3 2019 from ¥169,880,986.42 in Q3 2018, marking a rise of 19.0%[27] - Total non-current liabilities amounted to ¥7,537,910.88 in Q3 2019, compared to ¥6,943,118.17 in Q3 2018, indicating a growth of 8.6%[27] Shareholders' Equity - Net assets attributable to shareholders increased by 99.07% to CNY 1,223,483,240.18 compared to the end of the previous year[7] - Shareholders' equity rose to CNY 1,223,483,240.18, up from CNY 614,609,988.51, which is an increase of about 99%[20] - Shareholders' equity reached ¥1,231,330,577.47 in Q3 2019, up from ¥620,186,641.44 in Q3 2018, an increase of 98.2%[27] Cash Flow - Operating cash flow net amount increased by 63.44% to CNY 94,695,799.31 for the period from January to September[7] - The net cash flow from operating activities rose to ¥94,695,799.31, a 63.44% increase from ¥57,939,226.56, driven by increased cash receipts from sales[15] - The company reported a net cash outflow from investment activities of ¥393,663,162.69, compared to a net outflow of ¥63,627,537.14 in the previous year, indicating a significant increase in investment expenditures[34] - Cash inflow from financing activities totaled ¥639,308,789.08, a substantial increase from ¥110,502,407.00 in the same period last year[34] - The net cash flow from financing activities was ¥510,869,567.62, compared to a net outflow of ¥16,749,986.75 in the previous year, showing a strong improvement in financing[34] Other Financial Metrics - The weighted average return on net assets decreased by 5.22 percentage points to 9.76%[7] - Non-recurring gains and losses totaled CNY 2,401,495.07 for the period[10] - The company has not indicated any significant changes in its profit forecast for the upcoming reporting period[15] - R&D expenses for Q3 2019 were ¥9,297,903.04, a significant increase of 63.5% compared to ¥5,677,855.64 in Q3 2018[27] - The income tax expense for Q3 2019 was ¥5,774,253.90, compared to ¥3,987,257.25 in Q3 2018, reflecting a rise of 45.0%[31]